Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.

This study is currently recruiting participants.

Verified by Melbourne Health, October 2005

Sponsored by:	Melbourne Health
Information provided by:	Melbourne Health
ClinicalTrials.gov Identifier:	NCT00232245

Purpose

The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.

Condition	Intervention
Atrial Fibrillation	Drug: Fish oil

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome

Drug Information available for: Fish oil

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Melbourne Health:

Estimated Enrollment:	60
Study Start Date:	December 2003

Eligibility

Ages Eligible for Study:	18 Years to 88 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients who have had at least 2 previous episodes of atrial fibrillation and an implanted pacemaker.

Exclusion Criteria:

Patients with chronic atrial fibrillation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00232245

Contacts

Contact: Paul Sparks, MBBS,PhD, FRACP

0393427000 ext 27133

paul.sparks@mh.org.au

Locations

Australia, Victoria
Royal Melbourne hospital	Recruiting
Melbourne, Victoria, Australia, 3050
Contact: Paul Sparks, MBBS,PhD,FRACP 93427000 ext 27133 paul.sparks@mh.org.au
Contact: Fiona Sutherland 93427000 ext 27133 fiona.sutherland@mh.org.au

Sponsors and Collaborators

Melbourne Health

Investigators

Principal Investigator:

Paul Sparks

Melbourne Health

More Information

Study ID Numbers:	2003.216
Study First Received:	October 2, 2005
Last Updated:	October 2, 2005
ClinicalTrials.gov Identifier:	NCT00232245
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration

Study placed in the following topic categories:

Heart Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009